ProFecund: clinical trial

A clinical study performed to asess efficiency of ProFecund and ProFecund B

The chosen variant was that of a prospective interventional multicentre national study.

The study was conducted over a period of 18 months, from June 2016 to December 2017.

The term “multicentre national study” means that it was conducted simultaneously in nine national centres, under the supervision of eleven gynaecology and endocrinology specialists.

“Prospective interventional” means that the 189 participating women, with known fertility problems, were treated with ProFecund and monitored by their doctors throughout the administration of the drug.

The patients were divided into two groups. The 103 women in the first group received one ProFecund tablet daily. For those in the second group, the treatment was supplemented daily with one tablet and one capsule of NatalVit IQ (a multivitamin and mineral complex, plus DHA and EPA, two essential fatty acids).

The treatments lasted up to six months (they were discontinued if the patient got pregnant). During this time, their partners received one capsule of ProFecund B every day.

The results of the study were more than promising:

Out of 189 patients, 70 got pregnant

The success rate was therefore 37% or, in other words, more than one in three patients got pregnant. The chart below shows this success rate.

ProFecund: studio medico

Evolution of the number of pregnancies in relation to the number of months of treatment.

ProFecund: studio medico
Along with the number of new pregnancies, two other factors were looked into: ovulation and polycystic ovary syndrome.

Studiu medical ProFecund

Studiu medical ProFecund
The number of patients who had ovulation increased more than 4 times and the number of patients diagnosed with polycystic ovary syndrome decreased almost 3 times at the end of the study.

The conclusions of the ProFecund medical study are obvious

The supplement may be used by women trying to conceive.

The patented blend consisting of a combination of Vitex, Maca and active folate regulates the menstrual cycle, stimulates ovulation and increases the likelihood of getting pregnant.

Profecund multicentric interventional prospective study

Authors: Conf. Dr. Edu Antoine1,2 Sef Lucrari Dr. Sergiu Chirila3 Sef Lucrari Dr. Cristina Teodorescu Medic Primar Cercetator Stiintific1,2

    1. Obstetrics and Gynaecology Department, “Nicolae Malaxa” Clinical Hospital, Bucharest, Romania;
    2. “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania;
    3. Faculty of Medicine, “Ovidius” University of Constanta, Romania;
A Patented Blend Consisting of a Combination of Vitex agnus-castus Extract, Lepidium meyenii (Maca) Extract and Active Folate, a Nutritional Supplement for Improving Fertility in Women (Edu Antoine, Sergiu Chirila, Cristina Teodorescu; Maedica (Bucur) 2019 Sep;14(3):274-279.; doi: 10.26574/maedica.2019.14.3.274)

The ProFecund medical study is published in medical journals:

    1. Maedica – A Journal of Clinical Medicine no 3/2019
    2. PubMed
    3. nr 3/2019
    4. Medica Academica, sep 2019
    5. British Medical Journal (ed. in Romanian), sep 2019
    6. Medical Business, no 104 (2019)